RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:94080

Non-functioning paraganglioma

high confidenceDisorder

Also known as: Non-secreting paraganglioma

Publications

41

37.1th percentile

Trials

0

Interventional, condition-specific

Researchers

199

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare neuroendocrine tumor arising from neural crest-derived paraganglion cells (most often in the para-aortic region at the level of renal hilia, organ of Zuckerkandl, thoracic paraspinal region, bladder, and carotid body) not associated with catecholamine secretion. These tumors are usually clinically silent and symptoms, if present, are nonspecific and depend on the location of the tumor. Association with certain cancer-predisposing syndromes, such as multiple endocrine neoplasia, neurofibromatosis type 1 or von Hippel lindau syndrome, may be observed.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    41 matched papers (20 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 70 for broader category paraganglioma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

41

41 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

41 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

20 in the last 10 years · high confidence · 37.1th percentile (publications denominator)

Phrase hits: 41 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

199

Distinct author names in 41 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Houry Y2 papers · 2025

    Service d'Urologie du CHU Ibn Rochd de Casablanca, Maroc.

    Papers in Europe PMC
  2. 02
    Jha A2 papers · 2020

    Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.

    Papers in Europe PMC
  3. 03
    Kimura N2 papers · 2018

    Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.

    Papers in Europe PMC
  4. 04
    Abdellatif K1 paper · 2017

    Service d'urologie B, CHU Ibn Sina, Faculté de Médecine et de Pharmacie de Rabat- Université Mohamed V- Maroc.

    Papers in Europe PMC
  5. 05
    Aboutaib R1 paper · 2015

    Service d'Urologie du CHU Ibn Rochd de Casablanca, Maroc.

    Papers in Europe PMC
  6. 06
    Abrar FN1 paper · 2025

    Addis Ababa University, School of Medicine, Department of Surgery, Urology Unit, Ethiopia. Electronic address: fadil.nuredin@aau.edu.et.

    Papers in Europe PMC
  7. 07
    Ahmed A1 paper · 2011
    Papers in Europe PMC
  8. 08
    Ahmed AA1 paper · 2017

    Service d'urologie B, CHU Ibn Sina, Faculté de Médecine et de Pharmacie de Rabat- Université Mohamed V- Maroc.

    Papers in Europe PMC
  9. 09
    Alemu TN1 paper · 2025

    Addis Ababa University, School of Medicine, Department of Surgery, Urology Unit, Ethiopia.

    Papers in Europe PMC
  10. 10
    Allievi A1 paper · 2006

    Unidad A de Clínica Medica, Servicio de Cirugía General, Sección Endocrinología, Servicio de Gastroenterología, Servicio de Patología, Hospital Juan A. Fernández, Buenos Aires. hdelle@intramed.net

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 70 trials are registered for paraganglioma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

70 interventional trials matched paraganglioma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: paraganglioma

70

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Non-functioning paraganglioma" OR "Non-secreting paraganglioma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Non-functioning paraganglioma" OR "Non-secreting paraganglioma"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"paraganglioma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T04:37:16.590Z